Inspire Trust Co. N.A. Has $3.82 Million Stock Holdings in Pfizer Inc. $PFE

Inspire Trust Co. N.A. lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 15.4% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 150,000 shares of the biopharmaceutical company’s stock after purchasing an additional 20,000 shares during the quarter. Inspire Trust Co. N.A.’s holdings in Pfizer were worth $3,822,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. Fiduciary Alliance LLC increased its position in Pfizer by 46.4% during the 3rd quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company’s stock worth $3,701,000 after purchasing an additional 46,043 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new position in shares of Pfizer during the third quarter worth $3,019,000. Money Concepts Capital Corp lifted its stake in shares of Pfizer by 29.9% in the 3rd quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company’s stock valued at $6,325,000 after acquiring an additional 57,188 shares during the last quarter. Vista Investment Partners LLC lifted its stake in shares of Pfizer by 236.1% in the 3rd quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company’s stock valued at $1,774,000 after acquiring an additional 48,900 shares during the last quarter. Finally, Generali Investments CEE investicni spolecnost a.s. boosted its holdings in shares of Pfizer by 76.4% during the 3rd quarter. Generali Investments CEE investicni spolecnost a.s. now owns 109,269 shares of the biopharmaceutical company’s stock valued at $2,784,000 after acquiring an additional 47,319 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Erste Group nudged up its FY2026 and FY2027 EPS estimates (to $2.97 and $2.84 respectively), a modest improvement to street forecasts that supports earnings visibility. Erste Group estimate lift
• Positive Sentiment: Pfizer announced positive results from its BREAKWATER trial — a near-term pipeline win that can underpin future revenue and investor confidence if it advances toward approval/commercialization. Pfizer BREAKWATER trial results
• Positive Sentiment: Several bullish retail-focused pieces highlight Pfizer’s ~6% dividend yield, stable cash flows and defensive profile as reasons it could be a value/dividend play during market volatility. Those narratives support demand from income-focused investors. Massive News: Pfizer’s 6% Dividend Could Be Safer Than You Think
• Neutral Sentiment: Comparisons with AstraZeneca highlight that Pfizer trades cheaper and pays a higher yield, but AZN’s stronger growth targets temper PFE’s relative upside — useful context for allocation decisions. AstraZeneca vs. Pfizer
• Neutral Sentiment: Lists of high-dividend, low-volatility stocks include Pfizer, reinforcing its role as a defensive, income-oriented holding for some portfolios. 10 High Dividend Stocks With Low Volatility
• Negative Sentiment: Barclays initiated coverage with an underweight call, signaling fresh sell-side skepticism that can pressure the stock if other firms follow suit. Barclays initiates coverage with underweight
• Negative Sentiment: Critical commentaries warn that Pfizer’s ~6% yield carries risks (cash-flow pressure, payout sustainability, and valuation traps), fueling investor caution on dividend reliability. Pfizer: A Risky 6.3% Yield
• Negative Sentiment: Other analyst initiations noted in the press include bearish starts, adding to near-term sentiment pressure for the stock. Bearish analyst initiations

Pfizer Stock Performance

Shares of PFE stock opened at $26.66 on Friday. The stock has a market capitalization of $151.55 billion, a PE ratio of 19.60 and a beta of 0.47. The business’s 50 day simple moving average is $25.95 and its 200 day simple moving average is $25.31. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.94.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.09. The firm had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. The company’s revenue was down 1.2% compared to the same quarter last year. During the same quarter last year, the business earned $0.63 EPS. As a group, research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be issued a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a yield of 6.5%. Pfizer’s payout ratio is presently 126.47%.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on PFE. Zacks Research cut Pfizer from a “hold” rating to a “strong sell” rating in a report on Monday, January 26th. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $30.00 price objective on shares of Pfizer in a research note on Friday, October 31st. Scotiabank began coverage on shares of Pfizer in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 target price on the stock. TD Cowen reissued a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. Finally, Wolfe Research set a $24.00 price target on shares of Pfizer and gave the company an “underperform” rating in a research report on Wednesday, December 17th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, Pfizer has an average rating of “Hold” and an average target price of $27.84.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.